Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide
and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2
diabetes mellitus using metformin.